<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, due to the extreme negative cardiovascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, researchers are looking for more potential anti-inflammatory agents with fewer adverse effects than NSAIDs [
 <xref rid="B17-molecules-26-02831" ref-type="bibr">17</xref>]. As a result, EOs are now seen as promising targets for the next wave of anti-inflammatory treatments as well as they can inhibit transcription of NF-ÎºB and suppress the cascade of arachidonic acid [
 <xref rid="B18-molecules-26-02831" ref-type="bibr">18</xref>,
 <xref rid="B19-molecules-26-02831" ref-type="bibr">19</xref>].
</p>
